BiomX Merges with Adaptive Phage Therapeutics, Secures $50 Million Financing. In a significant development in the biotech sector, BiomX Inc. (NYSEAMERICAN: PHGE), a clinical-stage microbiome company, has announced its entry into a merger agreement with Adaptive Phage Therapeutics (APT). The merger is complemented by a concurrent financing deal amounting to $50 million, marking a major milestone for both entities involved.$バイオムエックス インク(PHGE.US)$ ...
$バイオムエックス インク(PHGE.US)$corporate news, BiomX (PHGE) shares more than doubled after the company agreed to merge with Adaptive Phage Therapeutics to create a phage therapy company. DexCom (DXCM) shares gained 8.4%. The
バイオムエックス インクに関するコメント
$Wisa Tech get in why it's cheap
In a significant development in the biotech sector, BiomX Inc. (NYSEAMERICAN: PHGE), a clinical-stage microbiome company, has announced its entry into a merger agreement with Adaptive Phage Therapeutics (APT). The merger is complemented by a concurrent financing deal amounting to $50 million, marking a major milestone for both entities involved. $バイオムエックス インク(PHGE.US)$
...
DexCom (DXCM) shares gained 8.4%. The
まだコメントはありません